0 0 0 0 0 0.00961538461538462 0.0384615384615385 0.0192307692307692
Sign Up Today X
Thanks for submitting the form.
Stockreport

InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904

InflaRx N.V. (IFRX)  More Company Research Source: GlobeNewswire
Last inflarx n.v. earnings: 8/14 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: inflarx.com/home/investors/press-releases/01-2018--inflarx-to-present-at-upcoming-investor-conferences.html
JENA, Germany, Dec. 11, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the World Health Organization (WHO) has granted the international nonproprietary (generic) name (INN) of “izicopan” to the Company for its orally available C5aR inhibitor, formerly known as INF904, in accordance with the WHO's Procedure for the Selection of Recommended International Nonproprietary Names (INN) for Pharmaceutical Substances. In the next step of this process, the name “izicopan” will be published in the recommended list of INNs. Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, commented: “InflaRx welcomes the granting of izicopan as the INN for INF904. We believe the promising clinical data recently reported in hidradenitis suppurativa and chronic spontaneous urticaria indicate the tremendous potential izicopan has, as a best-in-class oral [Read more]
IMPACT SNAPSHOT EVENT TIME: IFRX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
IFRX alerts
from News Quantified
IFRX
NEWS
IFRX
Earnings
IFRX
Analyst Actions
IFRX
SEC Filings
Stockreport

InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904

InflaRx N.V.  (IFRX) 
More Company Research Source: GlobeNewswire
Last inflarx n.v. earnings: 8/14 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: inflarx.com/home/investors/press-releases/01-2018--inflarx-to-present-at-upcoming-investor-conferences.html
JENA, Germany, Dec. 11, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the World Health Organization (WHO) has granted the international nonproprietary (generic) name (INN) of “izicopan” to the Company for its orally available C5aR inhibitor, formerly known as INF904, in accordance with the WHO's Procedure for the Selection of Recommended International Nonproprietary Names (INN) for Pharmaceutical Substances. In the next step of this process, the name “izicopan” will be published in the recommended list of INNs. Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, commented: “InflaRx welcomes the granting of izicopan as the INN for INF904. We believe the promising clinical data recently reported in hidradenitis suppurativa and chronic spontaneous urticaria indicate the tremendous potential izicopan has, as a best-in-class oral [Read more]
IMPACT SNAPSHOT
EVENT TIME:
IFRX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS